Arrowhead Research | ARWR - Stock


Arrowhead Research reported $-173.08M in Stock for its fiscal quarter ending in December of 2024.





Stock Change Date
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
Alnylam Pharmaceuticals USD 82.72M 7.34M Dec/2025
Anika Therapeutics USD 16.28M 638K Sep/2025
Arrowhead Research USD -173.08M 173.08M Dec/2024
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Incyte USD 101.06M 17.61M Dec/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Ligand Pharmaceuticals USD 9.13M 2.77M Dec/2025
Merck USD 6.44B 157M Sep/2025
Moderna USD 332M 92M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.42B 114M Sep/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
TG Therapeutics USD 125.59M 21.37M Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025